Holen Sie sich die Stockscreener-App
5.275
4.44%
-0.235
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MNKD?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$5.51
Offen:
$5.48
24-Stunden-Volumen:
2.30M
Relative Volume:
0.62
Marktkapitalisierung:
$1.62B
Einnahmen:
$248.37M
Nettoeinkommen (Verlust:
$11.74M
KGV:
105.50
EPS:
0.05
Netto-Cashflow:
$18.24M
1W Leistung:
+17.27%
1M Leistung:
+34.32%
6M Leistung:
+2.24%
1J Leistung:
-13.54%
1-Tages-Spanne:
$5.245
$5.52
1-Wochen-Bereich:
$4.50
$6.199
52-Wochen-Spanne:
$3.3812
$7.63
Mannkind Corp Stock (MNKD) Company Profile
Firmenname
Mannkind Corp
Sektor
Branche
Telefon
818-661-5000
Adresse
1 CASPER STREET, DANBURY, CA
Vergleichen Sie MNKD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
5.275 | 1.76B | 248.37M | 11.74M | 18.24M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.28 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.08 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
731.24 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.37 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-10 | Eingeleitet | Wedbush | Outperform |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-10-10 | Eingeleitet | Wedbush | Outperform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-03-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2018-02-28 | Herabstufung | Maxim Group | Hold → Sell |
| 2017-11-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-10-06 | Bestätigt | Maxim Group | Buy |
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-05-10 | Bestätigt | Piper Jaffray | Underweight |
| 2016-05-10 | Bestätigt | RBC Capital Mkts | Underperform |
| 2016-01-06 | Bestätigt | Piper Jaffray | Underweight |
| 2016-01-06 | Bestätigt | RBC Capital Mkts | Underperform |
| 2015-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Herabstufung | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-05-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Bestätigt | MLV & Co | Hold |
| 2015-04-16 | Bestätigt | RBC Capital Mkts | Outperform |
Alle ansehen
Mannkind Corp Aktie (MNKD) Neueste Nachrichten
MannKind Corporation stock prediction for this week2025 Market Overview & AI Enhanced Execution Alerts - Newser
MannKind Corporation recovery potential after sell offTrade Exit Summary & Community Consensus Trade Signals - Newser
MannKind stock price target raised to $11 by H.C. Wainwright on Tyvaso success - Investing.com
MannKind (MNKD) Expands United Therapeutics Deal Can New Platform Revenues Transform Its Long-Term Story? - simplywall.st
What to expect from MannKind Corporation in the next 30 daysBond Market & Weekly Chart Analysis and Trade Guides - Newser
MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump - simplywall.st
Can MannKind Corporation recover in the next quarterWeekly Market Outlook & Accurate Technical Buy Alerts - Newser
Mannkind Corporation shares rise 1.22% premarket after United Therapeutics' drug Tyvaso shows significant lung function improvement. - AInvest
Published on: 2025-09-03 02:55:27 - Newser
Can trapped investors hope for a rebound in MannKind CorporationJuly 2025 Selloffs & Reliable Trade Execution Plans - Newser
Forecasting MannKind Corporation price range with options dataIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Combining machine learning predictions for MannKind CorporationJuly 2025 Recap & Safe Capital Investment Plans - Newser
Can MannKind Corporation ride the EV waveShare Buyback & Target Return Focused Picks - خودرو بانک
Trend analysis for MannKind Corporation this weekMarket Activity Report & Real-Time Volume Spike Alerts - Newser
Does MannKind Corporation show high probability of reboundJuly 2025 Breakouts & Real-Time Market Trend Scan - Newser
Historical volatility pattern of MannKind Corporation visualized2025 Market Overview & Smart Allocation Stock Reports - Newser
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results - Stocktwits
Is MannKind Corporation stock a buy or sellQuarterly Performance Summary & Low Drawdown Momentum Ideas - خودرو بانک
Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7 - MSN
Applying chart zones and confluence areas to MannKind CorporationPortfolio Growth Summary & Weekly Sector Rotation Insights - Newser
What MACD and RSI say about MannKind CorporationMarket Sentiment Review & Verified Momentum Watchlists - Newser
Mannkind (MNKD) Surges 25% on Strategic Acquisition and Financing Hints – What’s Next? - AInvest
Full technical analysis of MannKind Corporation stockJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
United Therapeutics Shares Surge on Strong Lung-Drug Trial Results - citybiz
MannKind Corporation Reversal Rally May Surprise Bears getLinesFromResByArray error: size == 0 - kangso.co.kr
What momentum shifts mean for MannKind CorporationDay Trade & Fast Momentum Entry Tips - Newser
United’s Tyvaso surprise in IPF potentially opens $4B market - BioWorld MedTech
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - inkl
MannKind Stock Surges Anew: Buy or Hold? - StocksToTrade
Mannkind Soars 38.13% on Strategic Acquisition of scPharmaceuticals - AInvest
MNKD Shares Plunge: Should Investors Worry? - timothysykes.com
How to integrate MannKind Corporation into portfolio analysis toolsJuly 2025 EndofMonth & Real-Time Sentiment Analysis - Newser
Has MannKind Corporation formed a bullish divergence2025 Trade Ideas & Free Accurate Trade Setup Notifications - Newser
Is MannKind Corporation currently under institutional pressureGap Up & Safe Entry Trade Reports - خودرو بانک
H.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD) - MSN
Applying big data sentiment scoring on MannKind CorporationJuly 2025 PostEarnings & Safe Entry Zone Tips - Newser
How MannKind Corporation stock performs during market volatilityTrade Exit Summary & Risk Controlled Stock Alerts - Newser
How to recover losses in MannKind Corporation stockWall Street Watch & Verified Technical Signals - Newser
MannKind Corporation Could See a Relief Rally From Support getLinesFromResByArray error: size == 0 - kangso.co.kr
Candlestick signals on MannKind Corporation stock todayBond Market & Safe Capital Investment Plans - Newser
Regression analysis insights on MannKind Corporation performanceMarket Volume Report & Weekly High Momentum Picks - Newser
Is now a turning point for MannKind CorporationJuly 2025 EndofMonth & Weekly Top Gainers Alerts - Newser
Analyzing recovery setups for MannKind Corporation investors2025 Dividend Review & Fast Gaining Stock Strategy Reports - Newser
Published on: 2025-08-31 07:53:49 - Newser
What makes MannKind Corporation stock price move sharplyQuarterly Earnings Report & Low Risk High Reward Trade Ideas - Newser
When is the best time to exit MannKind CorporationMarket Sentiment Summary & Safe Entry Zone Tips - Newser
MannKind's Strategic Acquisition of scPharmaceuticals: A Catalyst for Diversified Growth and Long-Term Value Creation - AInvest
Finanzdaten der Mannkind Corp-Aktie (MNKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mannkind Corp-Aktie (MNKD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thomson David | EVP Genl Counsel & Secretary |
Jul 16 '25 |
Sale |
3.94 |
7,466 |
29,416 |
841,719 |
1.37%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):